The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease.

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the ...

The FDA based its approval on results from the LIBERTY-BP ADEPT (NCT04206553) phase 2 and 3 study, which found dupilumab effective for adults with moderate to severe bullous pemphigoid and met ...

FDA expands approval of Moderna's RSV vaccine to some adults under age 60 June 13, 2025 Plexi Images/GHI/UCG/Universal Images Group via Getty Images ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from ...

FDA expands Moderna's RSV vaccine approval to at-risk adults Jun. 13, 2025 6:05 AM ET Moderna, Inc. (MRNA) Stock By: Preeti Singh, SA News Editor 1 Comment ...

FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis after positive trial data.

FDA approval of Dupixent for the treatment of bullous pemphigoid (BP) provides a new therapeutic option for approximately 27,000 adults in the U.S. who suffer from this debilitating disease.

FDA Expands Indication for Levita Magnetics' Magnetic Surgical System with MARS® for Minimally Invasive Bariatric and Hiatal Hernia Repair Provided by PR Newswire Jun 18, 2025, 5:58:00 AM ...